Gossamer Bio Inc (GOSS) Actualités

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for...

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH...

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for...

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

- $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - Gossamer Bio, Inc. (Nasdaq: GOSS), a...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for...

Form 8-K - Current report

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

- $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage...